| 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 疫苗分部(元) | - | 525,603,747.32 | - | 3,387,077,070.32 |
| 诊断分部(元) | - | 826,900,057.38 | - | 762,995,761.68 |
| 体外诊断(元) | 1,608,658,214.56 | - | 1,533,354,630.91 | - |
| 疫苗(元) | 606,432,558.89 | - | 3,960,126,056.91 | - |
| 营业成本(元) | ||||
| 疫苗分部(元) | - | 157,586,097.82 | - | - |
| 诊断分部(元) | - | 202,594,089.02 | - | - |
| 体外诊断(元) | 563,498,614.00 | - | 454,296,564.09 | - |
| 疫苗(元) | 179,306,715.39 | - | 332,564,649.09 | - |
| 毛利(元) | ||||
| 疫苗分部(元) | - | 368,017,649.50 | - | - |
| 诊断分部(元) | - | 624,305,968.36 | - | - |
| 体外诊断(元) | 1,045,159,600.56 | - | 1,079,058,066.82 | - |
| 疫苗(元) | 427,125,843.50 | - | 3,627,561,407.82 | - |
| 毛利率(%) | ||||
| 疫苗分部(%) | - | 70.02 | - | - |
| 诊断分部(%) | - | 75.50 | - | - |
| 体外诊断(%) | 64.97 | - | 70.37 | - |
| 疫苗(%) | 70.43 | - | 91.60 | - |
| 收入构成(%) | ||||
| 疫苗分部(%) | - | 38.86 | - | 81.61 |
| 诊断分部(%) | - | 61.14 | - | 18.39 |
| 体外诊断(%) | 72.62 | - | 27.91 | - |
| 疫苗(%) | 27.38 | - | 72.09 | - |
| 毛利构成(%) | ||||
| 疫苗分部(%) | - | 37.09 | - | - |
| 诊断分部(%) | - | 62.91 | - | - |
| 体外诊断(%) | 70.99 | - | 22.93 | - |
| 疫苗(%) | 29.01 | - | 77.07 | - |